Navigation Links
NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
Date:6/10/2008

IV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2008 for PHN.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of NeurogesX' lead product candidate, NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks rel
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
7. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
8. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
9. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
10. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
11. Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... company serving the pharmaceutical, biotechnology, and medical device industries ... the United States , congratulates our ... the U.S. FDA for ibalizumab (TMB355). The FDA designates ... intended, alone or in combination with one or more ...
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... highlighted findings from a pre-clinical study published in ... Sciences ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ... anti-PD-L1 antibody (a checkpoint inhibitor), suppression of tumor ... be achieved when treating certain hematologic cancers and ...
(Date:2/27/2015)... Feb. 27, 2015  Following a bipartisan vote ... moved H.R. 284, the Medicare DMEPOS Competitive Bidding ... for Homecare (AAHomecare) released a statement praising the ... pass the legislation. "Today,s mark-up of ... Ways and Means Committee is a critical step ...
Breaking Medicine Technology:WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2
... INDIANAPOLIS, Oct. 4, 2011 Roche (SIX: RO, ROG; OTCQX: ... line in North America beyond physician offices and outpatient clinics ... for hospital and reference laboratories. The new line is expected ... subject to regulatory approval and other requirements. ...
... Eli Lilly and Company (NYSE: LLY ... achieving two of the company,s three environmental goals ahead of schedule. ... waste sent to landfills by about 50 percent and has reduced ... track to meet its energy goal. Lilly has improved the energy ...
Cached Medicine Technology:Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014 2Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities 2Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities 3
(Date:2/28/2015)... BC (PRWEB) February 28, 2015 Vancouver personal ... personal injury claims are affected by time limits. They stated ... weaken a person’s claim or even nullify it. Many a ... effects on a client’s rights under BC law. As a ... are affected by accidents should consult a personal injury lawyer ...
(Date:2/28/2015)... MD (PRWEB) February 28, 2015 For ... conference in person, the Mesothelioma Applied Research Foundation ... place on Tuesday, March 3, starting at 9:30 AM. ... requires no registration. The broadcast can be accessed through ... http://www.curemeso.org/symposium . , The Symposium is a unique ...
(Date:2/28/2015)... MO (PRWEB) February 28, 2015 ... provider of outsourced sales, marketing and supply chain ... client, BIOTA Botanicals, is bringing its award winning ... worldwide, BIOTA Botanicals’ products are specifically created to ... care experts, BIOTA is committed to marrying science ...
(Date:2/28/2015)... NY (PRWEB) February 28, 2015 A ... federal testosterone lawsuits that have been filed by law ... the second week in March, the Firm notes. ... website, parties involved in the federal litigation will meet ... matters related to prescription therapy treatments designed to raise ...
(Date:2/28/2015)... On Thursday, February 26th, Forbes published an ... Scammers To Steal Your Data , which stresses the ease ... a DIY phishing kit, or any kind of malware kit ... important point about how everyone’s cyber security is intertwined when ... compromising legitimate content management systems or blogs in order to ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4
... Industry Leader by the Economic Development Council ... ... Roskamp,Institute today was presented with the 2007 Innovation and Technology Award,by ... the innovative and technological advances it has made within,the scientific research ...
... LAF Funding Supports Cancer Research and Community-Based ... The Lance Armstrong Foundation,(LAF) recently awarded more ... cancer survivorship initiatives across the country., ... includes approximately $162,000,to six cancer survivorship community-based ...
... Tsao-Nivaggioli,Chief Executive Officer of Avicena Group, Inc. (OTC ... in an exclusive interview,with http://www.wallst.net scheduled ... interview,will be posted on http://www.wallst.net by ... interview will cover topics including Avicena Group,s market,potential, ...
... a puppy madly sniffing with affection gets an idea of ... a dogs appreciation of her two-legged friends. Now new research ... scents that affect whether or not we like somebody. ... who we like or dont like, said Wen Li, a ...
... Dec. 6 Orbel Corp., a supplier of,electroplating ... a,new 57,000 square foot facility in Easton, Pennsylvania. ... advanced production processes,increases Orbel,s manufacturing capacity and efficiency., ... include a,complete wet lab, a measurement/testing lab, and ...
... Vitamin ... Gummy for Acne, NEW YORK, Dec. ... business development consultancy BANKS., has,agreed to join Frutels, LLC as a member ... marketing experience in apparel,cosmetics, fragrance and fashion accessories to the Frutels effort.,Frutels, ...
Cached Medicine News:Health News:The Roskamp Institute Receives Award of Appreciation for Its Continued Innovative and Technological Advances 2Health News:Lance Armstrong Foundation Awards $1.5 Million in Grants 2Health News:WallSt.net Announces Upcoming Interview With CEO of Avicena Group 2Health News:Subliminal smells bias perception about a person's likeability 2Health News:Marketing Powerhouse Wendy Banks Joins Frutels' Advisory Board 2
Replacement burr for E0819A or E0819B Algerbrush rust ring remover. Dull finish....
0.5 mm replacement burr for Algerbrush rust ring remover (E0815 A). Burr can also be used with Algerbrush rust ring remover (E0815 B). Dull finish....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Medium 27 mm taper, distal end is straight to act as a guide for the tapered dilator which follows. Stainless steel. Round knurled handle with polished finish. Overall length: 3.9 inches....
Medicine Products: